LENZ Therapeutics annual current ratio
2020
2021
2022
2023
2024
2025
LENZ Therapeutics Current Ratio Growth & History (LENZ)
LENZ Therapeutics's current ratio was 14.23 for fiscal 2025.
View full LENZ Therapeutics company overviewLENZ Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 14.23 | −6.14 | −30.14% |
| 2024 | 2024-12-31 | 20.36 | 16.73 | +460.70% |
| 2023 | 2023-12-31 | 3.63 | −17.48 | −82.80% |
| 2022 | 2022-12-31 | 21.11 | −10.32 | −32.84% |
| 2021 | 2021-12-31 | 31.44 | 30.78 | +4674.13% |
| 2020 | 2020-12-31 | 0.66 | — | — |
LENZ Therapeutics quarterly current ratio
Q4.20
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 13.55 | −6.99 | −34.02% |
| Q1 2026 | 2026-03-31 | 10.40 | −12.69 | −54.96% |
| Q4 2025 | 2025-12-31 | 14.23 | −6.14 | −30.14% |
| Q3 2025 | 2025-09-30 | 12.69 | −15.94 | −55.68% |
| Q2 2025 | 2025-06-30 | 20.54 | −2.68 | −11.55% |
| Q1 2025 | 2025-03-31 | 23.09 | 11.62 | +101.28% |
| Q4 2024 | 2024-12-31 | 20.36 | 16.73 | +460.70% |
| Q3 2024 | 2024-09-30 | 28.63 | 9.58 | +50.30% |
| Q2 2024 | 2024-06-30 | 23.23 | 2.76 | +13.46% |
| Q1 2024 | 2024-03-31 | 11.47 | −7.38 | −39.14% |
| Q4 2023 | 2023-12-31 | 3.63 | −17.48 | −82.80% |
| Q3 2023 | 2023-09-30 | 19.05 | −3.03 | −13.71% |
| Q2 2023 | 2023-06-30 | 20.47 | −6.60 | −24.37% |
| Q1 2023 | 2023-03-31 | 18.85 | −8.08 | −30.01% |
| Q4 2022 | 2022-12-31 | 21.11 | −10.32 | −32.84% |
| Q3 2022 | 2022-09-30 | 22.07 | −13.52 | −37.99% |
| Q2 2022 | 2022-06-30 | 27.07 | −21.90 | −44.72% |
| Q1 2022 | 2022-03-31 | 26.93 | — | — |
| Q4 2021 | 2021-12-31 | 31.44 | 30.78 | +4674.13% |
| Q3 2021 | 2021-09-30 | 35.60 | — | — |
| Q2 2021 | 2021-06-30 | 48.96 | — | — |
| Q4 2020 | 2020-12-31 | 0.66 | — | — |
LENZ Therapeutics current ratio trends
Over the last five fiscal years, LENZ Therapeutics's current ratio increased from 0.66 to 14.23, a change of 13.57. The latest reported quarter, Q2 2026, shows 13.55.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review LENZ Therapeutics source filings ↗